Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: LemurHouse who wrote (315)	5/10/1999 5:59:00 PM
From: Nelson Chang	Read Replies (1) \| Respond to of 656

AFTER THE BELL - Immunex rises 11 to 118 NEW YORK, May 10 (Reuters) - Shares of Immunex Corp. rose sharply in Monday's post-session after the company said it plans to seek regulatory approval for expanded use of its drug Enbrel in patients with early, active rheumatoid arthritis. The company said results of a key trial were positive. The company also said it was advising doctors not to begin Enbrel in patients with an active infection after six deaths were reported among 25,000 patients taking it since November. Immunex traded at 118 on the Instinet broker system, up 11 from the regular close.